HCM causes the heart muscle to abnormally thicken, making it harder for the heart to pump blood effectively. According to the ...
SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of ...
ACACIA-HCM is a Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of aficamten compared to placebo on health-related quality of life in ...
Many drugs available and in development work by targeting proteins, an approach that comes with limitations. For one, proteins are not the root cause of disease, said Samir Ounzain, co-founder and CEO ...
MYQORZO launch momentum: approved in the U.S., Europe and China, with ~125 U.S. cardiovascular account specialists deployed, >700 REMS‑certified prescribers, >90% cardiology awareness, and early ...
– Topline Phase 2 data from the IMPROVE-ISCHEMIA clinical trial in Stable Angina also anticipated in 4Q 2023 – BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...
New research shows GLP-1 drugs may cut heart failure and cardiovascular risks in high‑risk patients, even as Medicare delays a pilot program to expand coverage for weight‑loss use. Observational ...
SOUTH SAN FRANCISCO, Calif., May 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that additional data arising from two analyses from SEQUOIA-HCM, (Safety, Efficacy, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results